PYPD News and Press, PolyPid Ltd. From 12/12/22

Meeting Scheduled for January 2023 PolyPid Recently Provided FDA with Currently Available Data from Completed SHIELD I Phase 3 Study in Advance of Meeting PETACH TIKVA, Israel, Dec. 12, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the ...

PolyPid ( NASDAQ: PYPD ) said it had received a written notice from Nasdaq saying that tit was not in compliance with the minimum bid price requirement for continued listing. The Company has been granted a period of 180 calendar days to regain compliance with the minimum bid price...

PETACH TIKVA, Israel, Dec. 09, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced it has received a written notice (the “Notice”)...

PETACH TIKVA, Israel, Nov. 29, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Phase 2 clinical data for D-PLEX 100 will be h...

PolyPid press release ( NASDAQ: PYPD ): Q3 GAAP EPS of -$1.71 misses by $1.19 . As of September 30, 2022, the Company had cash and cash equivalents and deposits in the amount of $18.1 million, including the $2.6 million upfront payment from ADVANZ PHARMA rece...

Company Intends to Meet with U.S. and EU Regulatory Authorities to Discuss Data from SHIELD I Phase 3 Study and Regulatory Pathway for D-PLEX 100 in First Quarter of 2023 Implemented a Cost Reduction Plan, Including a 20% Decrease in Headcount Across ...

PETACH TIKVA, Israel, Oct. 26, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its third quarter 2022 financial results...

PolyPid ( NASDAQ: PYPD ) announced on Thursday a cost reduction plan, including a 20% job cut across all departments as it expects the actions to extend tits cash runway into Q3 2023. The company expects to discuss regulatory pathway for D-PLEX100 for prevention o...

Reduction of Approximately 20% in Organization Headcount Company Expects to Extend Cash Runway into Q3 2023 PolyPid Intends to Discuss Regulatory Pathway for D-PLEX 100 for Prevention of Surgical Site Infections in Abdominal Surgery with U.S. and EU Regul...

Why The Stock Market Is Down Today But wait, the stock market crash is over. At least, that is what some retail traders thought after yesterday’s broad-sector bounce led by tech. Waking up to the stock market today painted a much different picture. Even with this as the case, in ...